ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular Therapeutics” or the Company”) (NYSE MKT: IMUC), a biotechnology company focused on the development of novel immune-based cancer therapies, announced the allowance of a Japanese patent relating to a technology for the treatment of brain cancer for which the Company holds an exclusive, worldwide license. The patent covers the treatment of brain cancer with a combination of a dendritic cell based vaccine combined either before or concurrently with the administration of chemotherapy. The Company believes that in the treatment of cancer, particularly cancers of the central nervous system such as glioblastoma multiforme (GBM), a dual therapeutic approach that includes the administration of a dendritic cell-based cancer vaccine combined with a regimen of chemotherapy could substantially enhance the clinical efficacy of treatment.
“The strengthening of our world-wide intellectual property protection for the treatment and detection of cancers further supports our developmental efforts and enhances our ability to license or partner our immunotherapeutic platforms,” said Manish Singh, Ph.D. President and CEO of ImmunoCellular Therapeutics. “It is with this in mind that we continue to pursue opportunities to solidify our intellectual property on a global scale.”
About ImmunoCellular Therapeutics, Ltd.
ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company has commenced a Phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma. To learn more about the Company, please visit
Forward-Looking Statements for ImmunoCellular Therapeutics
This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties, including the risk that the Japanese patent may not provide commercially significant protection for any of the Company’s products. Additional risks and uncertainties are described in IMUC’s most recently filed SEC documents, such as its most recent annual report on Form 10-K, all quarterly reports on Form 10-Q and any current reports on Form 8-K. IMUC undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.